Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

Seminars in Oncology

Volumn 29, Issue 5 SUPPL. 14, 2002, Pages 38-44

  Bunn Jr , Paul A ^a   Franklin, Wilbur ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKING AGENT; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; FEVER; GENE OVEREXPRESSION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MALAISE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING;

EID: 0037010087     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70089-4     Document Type: Conference Paper

References (51)

1. Kelly K, Kane MA, Bunn PA Jr: Growth factors in lung cancer: Possible etiologic role and clinical target. Med Pediatr Oncol 19:449-458, 1991
2. Chan DC, Geraci M, Bunn PA Jr: Anti-growth factor therapy for lung cancer. Drug Resist Update 1:377-388, 1998
3. Franklin WA: Diagnosis of lung cancer: Pathology of invasive and preinvasive neoplasia. Chest 117:80S-89S, 2000
4. Kurie JM, Shin HJC, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793, 1996
5. Polosa R, Prosperini G, Leir SH, et al: Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20:914-923, 1999
6. Franklin WA, Veve R, Hirsch FR, et al: Epidermal growth factor receptor (EGFR) family expression in lung cancer and premalignancy. Semin Oncol 29:3-14, 2002 (suppl 4)
7. Hirsch FR, Bunn PA, Miller YE, et al: Intermediate biomarker profile for lung cancer chemoprevention trials. Proc Am Soc Clin Oncol 20:322a, 2001 (abstr 1286)
8. Keith RL, Miller YE, Gemmill RM, et al: Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6:1616-1625, 2000
9. Berger MS, Gullick WJ, Greenfield C, et al: Epidermal growth factor receptors in lung cancer. J Pathol 152:297-307, 1987
10. Cerny T, Barnes DM, Haselton P, et al: Expression of epidermal growth factor receptor (EGFR) in human lung tumours. Br J Cancer 54:265-269, 1986
11. Sobol RE, Astarita RW, Hofeditz C, et al: Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst 79:403-407, 1987
12. Dazzi H, Haselton PS, Thatcher N, et al: Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 59:746-749, 1989
13. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancer: Relevance to prognosis. J Clin Oncol 15:2858-2865, 1997
14. Pfeiffer P, Clausen PP, Andersen K, et al: Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small cell lung cancer: An immunohistochemical study on cryosections. Br J Cancer 74:86-91, 1996
15. Veale D, Kerr N, Gibson GJ, et al: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 68:162-165, 1993
16. Rachwal WJ, Bongiorno PF, Orringer MB, et al: Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 72:56-64, 1995
17. Tateishi M, Ishida T, Mitsudomi T, et al: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50:7077-7080, 1990
18. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous lung carcinomas. Br J Cancer 77:663-669, 1998
19. Rusch V, Klimstra D, Venkatraman E, et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell cancer but does not predict tumor progression. Clin Cancer Res 3:515-522, 1997
20. Fontanini G, De Laurentiis M, Vignati S, et al: Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-III non-small cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249, 1998
21. D'Amico TA, Massey M, Herndon II JE, et al: A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
22. Ohsaki Y, Tanno S, Fujita Y, et al: Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603-607, 2000
23. Cox G, Jones JL, O'Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6:2349-2355, 2000
24. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9, 2001
25. Masui H, Moroyama T, Mendelsohn J: Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 46:5592-5598, 1986
26. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
27. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
28. Yang XD, Jia XC, Corvalan JR, et al: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23, 2001
29. Yang XD, Jia XC, Corvalan JR, et al: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 15:1236-1243, 1999
30. Figlin RA, Belldegrun A, Lohner ME, et al: ABX-EGF: A fully human anti-EGFR receptor antibody in patients with advanced cancer. Proc Am Soc Clin Oncol 20:276a, 2001 (abstr 1102)
31. Bonner JA, Raisch KP, Trummell HQ, et al: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Ctin Oncol 18:47S-53S, 2000
32. Bianco C, Bianco R, Tortora G, et al: Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6:4343-4350, 2000
33. Milas L, Mason K, Hunter N, et al: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701-708, 2000
34. Baselga J, Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60:33-40, 2000 (suppl 1)
35. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
36. Sirontnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
37. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
38. Pollack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739-748, 1999
39. Nelson JM, Fry DW: Akt, MAPK (Erkl/2), and p38 act in concert to promote apoptosis in response to erbB receptor family inhibition. J Biol Chem 276:14842-14847, 2001
40. Rao GS, Murray S, Ethier SP: Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 48: 1519-1528, 2000
41. Bos M, Mendelsohn J, Kim YM, et al: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3:2099-2106, 1997
42. Sun Y, Fry DW, Vincent P, et al: Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res 19:919-924, 1999
43. Raben D, Helfrich B, Chan D, et al: C225 anti-EGFR antibody potentiates radiation and chemotherapy cytotoxicity in human non-small cell lung cancer cells in vitro and in vivo. Proc Am Soc Clin Oncol 20:257a, 2001 (abstr 1026)
44. Ferry D, Hammond L, Ranson M, et al: Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study. Proc Am Soc Clin Oncol 19:3a, 2000 (abstr 5e)
45. Baselga J, Herbst R, LoRusso P, et al: Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Am Soc Clin Oncol 19:177a, 2000 (abstr 686)
46. Negoro S, Nakagawa K, Fukuoaka M, et al: Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 20:324a, 2001 (abstr 1292)
47. Perez-Soler R, Chachoua A, Huberman M, et al: A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310a, 2001 (abstr 1235)
48. Garrison MA, Tolcher A, McCreery H, et al: A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 20:72a, 2001 (abstr 283)
49. Shin DM, Nemunaitis J, Zinner RG, et al: A phase I clinical biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 20:82a, 2001 (abstr 324)
50. Miller VA, Johnson D, Heelan RT, et al: A pilot trial demonstrates the safety and efficacy of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:326a, 2001 (abstr 1301)
51. Hong WK, Arquette M, Nabell L, et al: Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 895)